Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 16, 2024

Conditions
Pulmonary Disease, Chronic ObstructiveLung Diseases, InterstitialPulmonary FibrosisHypoxemiaDyspneaOxygen Inhalation Therapy
Interventions
DEVICE

Nasal Delivery of High-Flow Air and Oxygen Therapy

They will receive high-flow air and oxygen via a dual lumen nasal cannula at rest. Participants will be administered the high-flow air and then titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.

DEVICE

Nasal Delivery of Oxygen Therapy

They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.

Trial Locations (2)

21224

Johns Hopkins Hospital Bayview Asthma and Allergy Center, Baltimore

212187

The Johns Hopkins Hospital, Baltimore

All Listed Sponsors
collaborator

American College of Chest Physicians

OTHER

lead

Johns Hopkins University

OTHER

NCT04170062 - Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest | Biotech Hunter | Biotech Hunter